Mesoblast (MESO) announced the United States FDA has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy, Revascor, Regenerative Medicine Advanced Therapy designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome, a potentially life threatening congenital heart condition.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MESO:
- Mesoblast’s Revascor Therapy Shows Promise in Heart Failure
- Mesoblast’s Revascor improves survival in heart failure patients
- Largest borrow rate increases among liquid names
- Mesoblast Announces Director Change and Shareholdings
- MESO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
